Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017 (2017), Article ID 7495914, 6 pages
https://doi.org/10.1155/2017/7495914
Research Article

Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

1Department of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1451, Houston, TX 77030, USA
2Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
3Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA

Correspondence should be addressed to Raymundo A. Quintana; ude.yrome@tniuqar

Received 16 June 2017; Accepted 20 August 2017; Published 26 September 2017

Academic Editor: Fritz C. Eilber

Copyright © 2017 Raymundo A. Quintana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Benjamin, P. H. Wiernik, and N. R. Bachur, “Adriamycin: A new effective agent in the therapy of disseminated sarcomas,” Medical and Pediatric Oncology, vol. 1, no. 1, pp. 63–76, 1975. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. O'Bryan, J. K. Luce, R. W. Talley, J. A. Gottlieb, L. H. Baker, and G. Bonadonna, “Phase II evaluation of adriamycin in human neoplasia,” Cancer, vol. 32, no. 1, pp. 1–8, 1973. View at Publisher · View at Google Scholar · View at Scopus
  3. R. M. O'Bryan, L. H. Baker, J. E. Gottlieb et al., “Dose response evaluation of adriamycin in human neoplasia,” Cancer, vol. 39, no. 5, pp. 1940–1948, 1977. View at Publisher · View at Google Scholar · View at Scopus
  4. D. D. von Hoff, M. W. Layard, P. Basa et al., “Risk factors for doxorubicin-induced congestive heart failure,” Annals of Internal Medicine, vol. 91, no. 5, pp. 710–717, 1979. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Mitani, D. Jain, T. M. Joska, B. Burtness, and B. L. Zaret, “Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radinuclide angiocardiography in the current era,” Journal of Nuclear Cardiology, vol. 10, no. 2, pp. 132–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Altena, P. J. Perik, D. J. van Veldhuisen, E. G. de Vries, and J. A. Gietema, “Cardiovascular toxicity caused by cancer treatment: strategies for early detection,” The Lancet Oncology, vol. 10, no. 4, pp. 391–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. G. Schwartz, W. B. McKenzie, J. Alexander et al., “Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography,” The American Journal of Medicine, vol. 82, no. 6, pp. 1109–1118, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Grenier and S. E. Lipshultz, “Epidemiology of anthracycline cardiotoxicity in children and adults,” Seminars in Oncology, vol. 25, no. 4, pp. 72–85, 1998. View at Google Scholar · View at Scopus
  9. J. P. Krischer, S. Epstein, D. D. Cuthbertson, A. M. Goorin, M. L. Epstein, and S. E. Lipshultz, “Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 1544–1552, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Nousiainen, E. Jantunen, E. Vanninen, and J. Hartikainen, “Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients,” British Journal of Cancer, vol. 86, no. 11, pp. 1697–1700, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. S. Legha, R. S. Benjamin, B. Mackay et al., “Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion,” Annals of Internal Medicine, vol. 96, no. 2, pp. 133–139, 1982. View at Publisher · View at Google Scholar · View at Scopus
  12. E. S. Casper, J. J. Gaynor, S. I. Hajdu et al., “A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high‐grade extremity soft tissue sarcoma and an analysis of prognostic factors,” Cancer, vol. 68, no. 6, pp. 1221–1229, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. G. N. Hortobagyi, H. Yap, S. W. Kau et al., “A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer,” American Journal of Clinical Oncology, vol. 12, no. 1, pp. 57–62, 1989. View at Publisher · View at Google Scholar
  14. J. Shapira, M. Gotfried, M. Lishner, and M. Ravid, “Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation,” Cancer, vol. 65, no. 4, pp. 870–873, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Zalupski, B. Metch, S. Balcerzak et al., “Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A southwest oncology group study,” Journal of the National Cancer Institute, vol. 83, no. 13, pp. 926–932, 1991. View at Publisher · View at Google Scholar · View at Scopus
  16. E. C. Van Dalen, H. J. H. Van Der Pal, H. N. Caron, and L. C. M. Kremer, “Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005008, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-F. Pichon, F. Cvitkovic, K. Hacene et al., “Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography,” In Vivo, vol. 19, no. 3, pp. 567–576, 2005. View at Google Scholar · View at Scopus
  18. H. Okumura, K. Iuchi, T. Yoshida et al., “Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity,” Acta Haematologica, vol. 104, no. 4, pp. 158–163, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. W. J. Reagan, M. York, B. Berridge, E. Schultze, D. Walker, and S. Pettit, “Comparison of Cardiac Troponin I and T, Including the Evaluation of an Ultrasensitive Assay, as Indicators of Doxorubicin-induced Cardiotoxicity,” Toxicologic Pathology, vol. 41, no. 8, pp. 1146–1158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Bertinchant, A. Polge, J. M. Juan et al., “Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings,” Clinica Chimica Acta, vol. 329, no. 1-2, pp. 39–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Cardinale, M. T. Sandri, A. Colombo et al., “Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy,” Circulation, vol. 109, no. 22, pp. 2749–2754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Cardinale, M. T. Sandri, A. Martinoni et al., “Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy,” Journal of the American College of Cardiology, vol. 36, no. 2, pp. 517–522, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Cardinale, M. T. Sandri, A. Martinoni et al., “Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy,” Annals of Oncology, vol. 13, no. 5, pp. 710–715, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Ky, M. Putt, H. Sawaya et al., “Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab,” Journal of the American College of Cardiology, vol. 63, no. 8, pp. 809–816, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Cil, A. M. Kaplan, A. Altintas, A. M. Akin, S. Alan, and A. Isikdogan, “Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: A prospective series,” Clinical Drug Investigation, vol. 29, no. 2, pp. 131–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. T. Meinardi, D. J. Van Veldhuisen, J. A. Gietema et al., “Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients,” Journal of Clinical Oncology, vol. 19, no. 10, pp. 2746–2753, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Ryberg, D. Nielsen, T. Skovsgaard, J. Hansen, B. V. Jensen, and P. Dombernowsky, “Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3502–3508, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. J. A. Neidhart, D. Gochnour, R. Roach, D. Hoth, and D. Young, “A comparison of mitoxantrone and doxorubicin in breast cancer,” Journal of Clinical Oncology, vol. 4, no. 5, pp. 672–677, 1986. View at Publisher · View at Google Scholar · View at Scopus
  31. L. A. Smith, V. R. Cornelius, C. J. Plummer et al., “Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials,” BMC Cancer, vol. 10, article 337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. M. Young, T. Dhillon, and M. Bower, “Cardiotoxicity after liposomal anthracyclines,” Lancet Oncology, vol. 5, no. 11, p. 654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Gabizon, O. Lyass, G. J. Berry, and M. Wildgust, “Cardiac safety of pegylated liposomal doxorubicin (Doxil®/Caelyx®) demonstrated by endomyocardial biopsy in patients with advanced malignancies,” Cancer Investigation, vol. 22, no. 5, pp. 663–669, 2004. View at Publisher · View at Google Scholar · View at Scopus